GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Degree of Financial Leverage

Absci (ABSI) Degree of Financial Leverage : 0.67 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Absci Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Absci's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 0.67. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Absci's Degree of Financial Leverage or its related term are showing as below:

ABSI's Degree of Financial Leverage is ranked better than
66.22% of 1501 companies
in the Biotechnology industry
Industry Median: 0.96 vs ABSI: 0.67

Absci Degree of Financial Leverage Historical Data

The historical data trend for Absci's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Degree of Financial Leverage Chart

Absci Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
- 0.91 0.18 2.12 0.71

Absci Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 -1.02 1.28 0.71 0.67

Competitive Comparison of Absci's Degree of Financial Leverage

For the Biotechnology subindustry, Absci's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Absci's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Absci's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Absci's Degree of Financial Leverage falls into.



Absci Degree of Financial Leverage Calculation

Absci's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -1.16 (Mar. 2024) / -1.09 (Mar. 2023) - 1 )/( -108.216 (Mar. 2024) / -98.742 (Mar. 2023) - 1 )
=0.0642/0.0959
=0.67***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Absci  (NAS:ABSI) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Absci Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Absci's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Absci (ABSI) Business Description

Industry
Traded in Other Exchanges
N/A
Address
18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Executives
Frans Van Houten director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj director 400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman officer: General Counsel 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick officer: VP, CCPAO 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh director C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain director, 10 percent owner, officer: President and Chief Executive 18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis director INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p. director, 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc 10 percent owner 1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel officer: Chief Business Officer 101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660